Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
- 20 Downloads
KeywordsAnaplastic large cell lymphoma ALK+ve Crizotinib ALK Targeted therapy
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
This is a retrospective data analysis and no patient identifying information is being included in the manuscript. As per our Institution policy, we don’t require ethical approval for retrospective analysis.
- 3.Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J et al (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 14(6):472–480CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Redaelli S, Farina F, Stasia A, Ceccon M, Mologni L, Messa C et al (2013) High response rates to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. Blood 122:368Google Scholar